Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025

Conference Call and Webcast at 8:30 AM Eastern Time

NEW YORK , Oct. 29, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD)  ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, November 12, 2025, at 8:30 AM ET. During the call,  Lishan Aklog, M.D. , Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition,  Dennis McGrath , Lucid's Chief Financial Officer, will discuss the Company's third quarter 2025 financial results.

The webcast will be available at the investor relations section of the Company's website at luciddx.com .  Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com .

About Lucid Diagnostics

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard ^® Esophageal DNA Test , performed on samples collected in a brief, noninvasive office procedure with its EsoCheck ^® Esophageal Cell Collection Device , represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com .

View original content to download multimedia: https://www.prnewswire.com/news-releases/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-november-12-2025-302597099.html

SOURCE Lucid Diagnostics